Prosecution Insights
Prosecution Insights
7 pending office actions • 4 clients • 7 examiners • 5 art units • 0 of 7 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 5 (71%) |
| Double-patenting only | 1 (14%) |
| No statute on record | 1 (14%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WEDDINGTON, KEVIN E | 1 | 75.3% | +10.0% |
| BORALSKY, LUKE ALAN | 1 | 100.0% | +0.0% |
| MOU, LIYUAN | 1 | 42.9% | +56.4% |
| RODRIGUEZ, RAYNA B | 1 | 33.0% | +20.6% |
| ROBINSON, MIKHAIL O'DONNEL | 1 | 57.5% | +42.7% |
| SOROUSH, LAYLA | 1 | 40.5% | +43.0% |
| SIMMONS, CHRIS E | 1 | 34.5% | +19.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18572715 | 25-Hydroxy-Cholest-5-En-3-Sulfate Choline and Methods for Preparing, and Uses of, Same | BORALSKY, LUKE ALAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18034411 | RIFAXIMIN LIQUID FORMULATIONS FOR USE IN THE TREATMENT OF SICKLE CELL DISEASE | MOU, LIYUAN | 77d overdue |
| 17913844 | SOLID DISPERSIONS OF RIFAXIMIN FOR THE TREATMENT OF OVERT HEPATIC ENCEPHALOPATHY | ROBINSON, MIKHAIL O'DONNEL | 73d overdue |
| 18008605 | USE OF OXYGENATED CHOLESTEROL SULFATES FOR TREATING INFLAMMATORY CONDITIONS | RODRIGUEZ, RAYNA B | 66d overdue |
| 19299563 | Solid Dispersion Forms of Rifaximin | WEDDINGTON, KEVIN E | 43d overdue |
| 17814474 | TOPICAL COMPOSITIONS COMPRISING A MACROLIDE IMMUNOSUPPRESSANT | SOROUSH, LAYLA | — |
| 17529818 | USE OF METHYLNALTREXONE AND RIFAXIMIN FOR TREATMENT OF INCREASED GUT PERMEABILITY OR ASSOCIATED DISORDERS | SIMMONS, CHRIS E | — |
| Client (Assignee) | Pending OAs |
|---|---|
| BAUSCH HEALTH IRELAND LIMITED | 4 |
| Salix Pharmaceuticals, Inc. | 1 |
| Durect | 1 |
| U.S. Government | 1 |
| Art Unit | Apps |
|---|---|
| 1628 | 2 |
| 1622 | 2 |
| 1629 | 1 |
| 1624 | 1 |
| 1627 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19299563 | Solid Dispersion Forms of Rifaximin | Salix Pharmaceuticals, Inc. | WEDDINGTON, KEVIN E | 1629 | §103 | Non-Final OA | 43d overdue | Pending | Aug 14, 2025 |
| 18572715 | 25-Hydroxy-Cholest-5-En-3-Sulfate Choline and Methods for Preparing, and Uses of, Same | Durect Corporation | BORALSKY, LUKE ALAN | 1624 | DP | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18034411 | RIFAXIMIN LIQUID FORMULATIONS FOR USE IN THE TREATMENT OF SICKLE CELL DISEASE | BAUSCH HEALTH IRELAND LIMITED | MOU, LIYUAN | 1628 | Other | Non-Final OA | 77d overdue | Pending | Apr 28, 2023 |
| 18008605 | USE OF OXYGENATED CHOLESTEROL SULFATES FOR TREATING INFLAMMATORY CONDITIONS | The United States Department of Veterans Affairs | RODRIGUEZ, RAYNA B | 1628 | §103 | Non-Final OA | 66d overdue | Pending | Dec 06, 2022 |
| 17913844 | SOLID DISPERSIONS OF RIFAXIMIN FOR THE TREATMENT OF OVERT HEPATIC ENCEPHALOPATHY | BAUSCH HEALTH IRELAND LIMITED | ROBINSON, MIKHAIL O'DONNEL | 1627 | §103 | Final Rejection | 73d overdue | Pending | Sep 23, 2022 |
| 17814474 | TOPICAL COMPOSITIONS COMPRISING A MACROLIDE IMMUNOSUPPRESSANT | BAUSCH HEALTH IRELAND LIMITED | SOROUSH, LAYLA | 1622 | §103 | Non-Final OA | — | Pending | Jul 22, 2022 |
| 17529818 | USE OF METHYLNALTREXONE AND RIFAXIMIN FOR TREATMENT OF INCREASED GUT PERMEABILITY OR ASSOCIATED DISORDERS | BAUSCH HEALTH IRELAND LIMITED | SIMMONS, CHRIS E | 1622 | §103 | Non-Final OA | — | Pending | Nov 18, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial